Lixisenatide – Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes

Celeste C L Quijazon¹ and Mansur E Shomali²

¹. Senior Fellow in Endocrinology, Diabetes and Metabolism; ². Program Director, Endocrinology, Diabetes and Metabolism Training Program, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Union Memorial Hospital

Abstract
The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency of glycylated haemoglobin (HbA1c) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycaemia, glucagon suppression and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.

Keywords
Lixisenatide, glucagon-like peptide-1 receptor agonist, type 2 diabetes

Type 2 diabetes is a progressive disease of the beta cells characterised by declining insulin secretion and varying degrees of insulin resistance resulting in hyperglycaemia. It is a chronic progressive disease of increasing incidence. In the US, 25.6 million people aged over 20 years have type 2 diabetes¹ and the prevalence is projected to increase to 36 million people in the next 20 years.² This trend follows that of the obesity epidemic. Patients with type 2 diabetes are at increased risk of microvascular and macrovascular complications (neuropathy, renal disease, retinopathy, myocardial infarction, cerebrovascular accident and peripheral vascular disease). Most patients need lifestyle changes and polypharmacy to control hyperglycaemia.

The American Association of Clinical Endocrinologists and American Diabetes Association guidelines recommend lifestyle changes and metformin as first-line therapy.¹⁴ The glucagon-like peptide-1 (GLP-1) receptor agonist class of medications may be used, typically as part of combination therapy, and may have certain advantages over older medications. GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner (thus having a low risk of hypoglycaemia), suppress glucagon secretion, improve beta cell function, slow down gastric emptying, and promote early satiety and consequent weight loss.⁶ In addition, GLP-1 agonists have potential cardiovascular benefits with weight reduction, improvements in lipid profile and blood pressure, and decreased markers for cardiovascular risk and inflammation (including C-reactive protein).⁴ GLP-1 receptor agonists approved by the US Food and Drug Administration are twice-daily exenatide (Byetta®, Amylin Pharmaceuticals, Inc. and Lilly USA, LLC) and once-daily liraglutide (Victoza®, Novo Nordisk). This article reviews lixisenatide (Lyzumia®, AVE0010, ZP10), an investigational once-daily GLP-1 receptor agonist in Phase III development for the treatment of type 2 diabetes, which is being developed by Sanofi-aventis under license from Zealand Pharma A/S.⁸

Pharmacology
Lixisenatide is a 44-amino-acid peptide based on exendin-4 and modified to avoid rapid degradation by dipeptidyl peptidase-IV.¹⁰ The modification consists of the deletion of one proline residue and addition of six lysine residues at the C-terminal.¹¹ While the affinity of exendin-4 for the GLP-1 receptor is similar to that of human GLP-1, the affinity of lixisenatide for the GLP-1 receptor is four times greater than that of human GLP-1 (see Figure 1 and Table 1). Lixisenatide is also highly selective for the GLP-1 receptor.¹² Pharmacokinetics studies show that maximum lixisenatide plasma concentration (Cmax) of 84 pg/ml is seen two hours (tmax) after the subcutaneous injection of lixisenatide 20 μg.¹³ The half-life (t½) is 2.6 ± 1 hours.³ Lixisenatide is filtered in the glomerulus and degraded in the renal tubules.¹⁴ Pharmacokinetic parameters for lixisenatide and the other GLP-1 receptor agonists are shown in Table 1.

Preclinical Studies
In a study using rat insulinoma cell line INS-1, lixisenatide protected B-cells against fatty acid and cytokine-induced apoptosis¹⁵ and inhibition of cytokine-induced apoptosis was significantly greater with lixisenatide and exendin-4 than with human GLP-1. Moreover, the combination of insulin glargine with lixisenatide or exendin-4 significantly reduced apoptosis compared with each agent alone.¹⁶
The insulin secretion pattern was studied in isolated pancreas from male Zucker diabetic fatty (ZDF) rats treated with lixisenatide and compared with isolated pancreas from lean and obese ZDF rats not treated with lixisenatide. Biphasic insulin secretion was preserved in the lixisenatide-treated obese ZDF rats, similar to what happened in lean controls, but was absent in older obese ZDF rats. In a study using human islet cells, lixisenatide showed dose-dependent improvement of glucose-stimulated insulin secretion.

Improvement of oral glucose tolerance with lixisenatide was shown in animal studies (obese ZDF rats, db/db mice and dogs). Decreased post-prandial glucose excursion following a mixed meal was seen in mongrel dogs. Marked reductions in glucose levels and glycosylated haemoglobin (HbA1C) were shown in lixisenatide-treated animals compared with saline-treated animals.

In a comparison study of dogs treated with lixisenatide or liraglutide, blood glucose excursion following glucose challenge in oral glucose tolerance tests was significantly lower in dogs treated with lixisenatide. A similar effect was seen in C57BL/6j mice following a liquid meal. Starting at different doses, both lixisenatide (1 μg/kg) and liraglutide (500 μg/kg) inhibited gastric emptying in Wistar rats.

Lixisenatide was shown to be cardioprotective in a study on isolated Langendorff-perfused rat hearts in which the left anterior descending coronary artery was transiently occluded for 45 minutes and then reperfused for 120 minutes. There was significant reduction in the infarct size with lixisenatide compared with vehicle control.

**Figure 1: Structure of the Glucagon-like Peptide-1 Receptor Agonists Liraglutide, Exenatide and Lixisenatide**

The amino acid sequence of three glucagon-like peptide-1 (GLP-1) receptor agonists are shown in comparison to the sequence of human GLP-1; differences with human GLP-1 are indicated by blue circles; differences between exenatide and lixisenatide are shown by purple circles. Sources: data taken from Werner, et al., 2010 and Nauck, 2011 with permission.

**Figure 2: Dose-dependent Effects of Lixisenatide On Glycosylated Haemoglobin in a Phase II Clinical Trial**

<table>
<thead>
<tr>
<th>Dose (μg)</th>
<th>LS mean change in HbA1C (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>0.18</td>
<td>p&lt;0.0056</td>
</tr>
<tr>
<td>10</td>
<td>0.47</td>
<td>p&lt;0.0033</td>
</tr>
<tr>
<td>20</td>
<td>0.69</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>30</td>
<td>0.76</td>
<td>p&lt;0.0001</td>
</tr>
</tbody>
</table>

Base overall mean: HbA1C = 7.55 %

HbA1C = glycosylated haemoglobin; LS = least squares. No significant differences were seen between once daily and twice daily dosing. Source: adapted from Ratner RE, et al., 2010 with permission.

**Table 1: Pharmacokinetics of Available Glucagon-like Peptide-1 Receptor Agonists**

<table>
<thead>
<tr>
<th>GLP-1 Receptor Agonist</th>
<th>Affinity</th>
<th>GLP-1 Receptor Affinity</th>
<th>Dosing Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human GLP-1</td>
<td>~1–2 minutes</td>
<td>~1x</td>
<td>Once daily</td>
</tr>
<tr>
<td>Exenatide</td>
<td>~2.4 hours</td>
<td>~1x</td>
<td>Twice daily</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>~13 hours</td>
<td>~1x</td>
<td>Once daily</td>
</tr>
<tr>
<td>Exenatide LAR</td>
<td>~2 weeks</td>
<td>~1x</td>
<td>Once weekly</td>
</tr>
<tr>
<td>Lixisenatide</td>
<td>~2.6 hours</td>
<td>~4x</td>
<td>Once daily</td>
</tr>
</tbody>
</table>

GLP-1 = glucagon-like peptide-1; LAR = long-acting release.

**Phase II Studies**

A dose-finding study was undertaken in patients with type 2 diabetes not controlled by metformin. This was a multinational, 13-week, randomised, double-blind, parallel-group, placebo-controlled study that enrolled 542 patients inadequately controlled after at least three months of metformin therapy. Participants had a mean age of 56 ± 9 years with mean disease duration of 6.6 ± 5 years, mean body mass index (BMI) of 31.9 ± 4 kg/m², and mean baseline HbA1C of 7.5 ± 0.6 %. Participants were randomised to one of 12 groups: lixisenatide (5, 10, 20 or 30 μg) administered once or twice daily or four volume-matched placebo treatments administered twice daily. All lixisenatide groups experienced dose-dependent reductions in HbA1C ranging from 0.47 % to 0.76 % in the once-daily regimen and from 0.65 % to 0.87 % in the twice-daily regimen compared with placebo (see Figure 2).

Secondary efficacy endpoints were the percentage of patients achieving HbA1C of <7 % and <6.5 %, changes in body weight, fasting
Diabetes Management

Table 2: Overview of Phase III Clinical Trials of Lixisenatide

<table>
<thead>
<tr>
<th>Study Goal Description</th>
<th>Trial Registration No.</th>
<th>No. Subjects</th>
<th>Completion Date</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>GetGoal-Mono</td>
<td>NCT00688701[^1^]</td>
<td>361</td>
<td>December 2009</td>
<td>Significant decrease in HbA1C, 2hr-PPG, and FPG; significant number of patients achieving HbA1C &lt;7 % and &lt;6.5 %</td>
</tr>
<tr>
<td>GetGoal-L-Asia</td>
<td>NCT0066658[^2^]</td>
<td>311</td>
<td>June 2010</td>
<td>Significant decrease in HbA1C, 2hr-PPG, glucose excursion, average 7-point SMPG; significant number of patients achieving HbA1C &lt;7 % and &lt;6.5 %</td>
</tr>
<tr>
<td>GetGoal-X</td>
<td>NCT00707031[^3^]</td>
<td>634</td>
<td>November 2010</td>
<td>Lixisenatide had similar HbA1C lowering and weight loss effects as exenatide</td>
</tr>
<tr>
<td>GetGoal-F1</td>
<td>NCT00763451[^7^]</td>
<td>450</td>
<td>January 2011</td>
<td>Both 1-step and 2-step titration regimens were effective and well-tolerated</td>
</tr>
<tr>
<td>GetGoal-P</td>
<td>NCT00763815[^8^]</td>
<td>450</td>
<td>June 2011</td>
<td>Not available</td>
</tr>
<tr>
<td>Lixisenatide versus sitagliptin as add-on to metformin in patients with type 2 diabetes, evaluating effects on glycaemic control and body weight in 24 weeks</td>
<td>NCT00976937[^10^]</td>
<td>~300</td>
<td>April 2011</td>
<td>Not available</td>
</tr>
<tr>
<td>Lixisenatide as add-on to metformin and insulin glargine in patients with type 2 diabetes compared with placebo, evaluating effects on glycaemic control in 24 weeks</td>
<td>NCT00975286[^11^]</td>
<td>~450</td>
<td>September 2011</td>
<td>The combination of basal insulin and lixisenatide reduced HbA1C and significantly improved 2hr-PPG</td>
</tr>
<tr>
<td>ELIXA</td>
<td>NCT01472500[^12^]</td>
<td>~6,000</td>
<td>October 2013</td>
<td>Ongoing study</td>
</tr>
</tbody>
</table>

[^1^]: Trial registration number.
[^2^]: Significant reduction in body weight was seen in lixisenatide-treated patients, which was significant in the 20 μg once daily (-3.01 ± 0.41 kg), 50 μg once daily (-3.47 ± 0.41 kg), and 10 μg twice daily (-3.89 ± 0.41 kg) groups compared with placebo (-1.94 ± 0.32 kg). Significant reductions in fasting plasma glucose were observed in the 30 μg once daily (-23.76 ± 4.50 mg/dl), 10 μg twice daily (-17.64 ± 4.32 mg/dl), 20 μg twice daily (-20.34 ± 4.50 mg/dl), and 30 μg twice daily (-25.56 ± 4.50 mg/dl) groups compared with placebo (-3.78 ± 3.42 mg/dl). Mean two-hour post-prandial glucose concentrations in all lixisenatide groups showed a significant reduction by comparison with placebo. The study indicated that efficacy was similar between the once- and twice-daily regimens and that there was a dose-response relationship. A dose of 20 μg lixisenatide once daily demonstrated the best efficacy/tolerability ratio. The data suggest further increases in the dose may not provide added benefit.

[^10^]: In a Phase II randomised, double-blind, placebo-controlled study involving 64 patients, lixisenatide once or twice daily was added to metformin and/or a sulfonylurea for 28 days. The study measured the effects of lixisenatide on post-prandial change in blood glucose following a standardised breakfast and on levels of fasting and mean plasma glucose and HbA1C. It also evaluated the safety and tolerability of the drug. The lixisenatide dose started at 5 μg subcutaneous once daily or twice daily and was increased by 2.5 μg every five days to a maximum dose of 20 μg. On day 28,
post-prandial blood glucose levels following a standardised breakfast, as well as mean plasma glucose and HbA1C levels, were significantly reduced in both the once-daily and twice-daily lixisenatide 20 μg groups compared with placebo.25

**Phase III Clinical Trial Programme**

The GetGoal clinical trial programme initially consisted of nine Phase III trials evaluating the efficacy and safety of lixisenatide in the treatment of patients with type 2 diabetes as monotherapy or in combination with different oral antidiabetes agents and/or insulin. Additional studies have been added to the GetGoal clinical programme, including randomised studies comparing lixisenatide to sitagliptin and a large clinical trial evaluating cardiovascular outcomes with lixisenatide in a type 2 diabetes patient who had had a recent acute coronary syndrome. The trials began in May 2008 and 4,300 patients have been enrolled in total.26 At the time of writing, the results of some of these trials have been made available as press releases, or have been presented at scientific meetings and published in abstract form. Table 2 shows a summary of the clinical trial programme.

**GetGoal-Mono**

GetGoal-Mono was a 12-week, double-blind, randomised controlled trial that assessed the efficacy and safety of lixisenatide as monotherapy for type 2 diabetes.27 A total of 361 type 2 diabetes patients not on any diabetes medication were randomised to two of four groups: lixisenatide two-step titration (10 μg once daily for one week, followed by 15 μg once daily for one week, and 20 μg once daily thereafter; n=120), lixisenatide one-step titration (10 μg once daily for two weeks, and 20 μg once daily thereafter; n=119), placebo two-step titration (n=61), or placebo one-step titration (n=61). Patients had a mean age of 54 years, mean disease duration of 2.5 years, and HbA1C in the range 7–10%.

In the lixisenatide groups, HbA1C decreased significantly (p<0.0001) by comparison with placebo (lixisenatide two-step group -0.73 ± 0.12 %; lixisenatide one-step group -0.85 ± 0.12 %; placebo -0.19 ± 0.12 %). At the end of the study, the lixisenatide groups included significantly more patients with HbA1C ≤6.5% (lixisenatide two-step group 31.9 %; lixisenatide one-step group 25.4 %; placebo 12.5 %) and HbA1C <7.0 % (lixisenatide two-step group 52.2 %; lixisenatide one-step group 46.5 %; placebo 26.8 %). They also had significantly higher reductions in two-hour post-prandial glucol levels (lixisenatide two-step group -81.18 ± 4.56 mg/dl; lixisenatide one-step group -98.46 ± 9.9 mg/dl; placebo -11.7 ± 10.08 mg/dl) and fasting plasma glucose levels (lixisenatide two-step group -12.24 ± 4.5 mg/dl; lixisenatide one-step group -16.02 ± 4.5 mg/dl; placebo 3.42 ± 4.68 mg/dl).27

**GetGoal-L-Asia**

GetGoal-L-Asia was a 24-week multicenter, randomised, double-blind, placebo-controlled clinical study, evaluated the efficacy and safety of lixisenatide in type 2 diabetes patients insufficiently controlled on metformin.28 The patients had a mean age of 57.4 years, a disease duration of 6.8 years, a BMI of 33.6 kg/m², and HbA1C levels of 8%. The decrease in HbA1C with lixisenatide (-0.79 ± 0.05 %) was comparable with that seen with exenatide (-0.96 ± 0.05 %; LS mean difference 0.17 [95 % CI 0.03–0.30]; p=0.17). Similar percentages of patients achieved HbA1C <7% with lixisenatide (48.5 %) and with exenatide (49.8 %). The mean decrease in body weight was comparable between the lixisenatide and exenatide groups.29

As an add-on therapy to metformin, lixisenatide significantly reduced HbA1C levels and improved two-hour post-prandial glucose and fasting plasma glucose levels compared with placebo.40 Moreover, patients on lixisenatide experienced a significant decrease in body weight compared with those on placebo.29 At 24 weeks, lixisenatide significantly reduced HbA1C compared with placebo (-0.85 versus -0.10%; p<0.0001). Lixisenatide also significantly improved two-hour PPG (after a standardised meal test) (-6.19 versus -0.21 mmol/l), FPG (-0.99 versus -0.36 mmol/l), and body weight (-1.76 versus -0.93 kg) and increased the proportion of patients achieving HbA1C <7.0 % (36.4 versus 13.5 %) (p<0.0001).

**GetGoal-L**

GetGoal-L is another 24-week clinical study in which 495 patients were randomised either to lixisenatide or placebo in addition to basal insulin with or without metformin. Compared with placebo, lixisenatide significantly decreased mean HbA1C (p=0.0002), improved post-prandial glucose following a standardised meal (p<0.0001) and reduced mean body weight (p<0.0001).

---

**Table 3: Additional Results for Lixisenatide versus Placebo from the GetGoal-L-Asia Study**

<table>
<thead>
<tr>
<th></th>
<th>Lixisenatide</th>
<th>Placebo</th>
<th>LS Mean Difference (95 % CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-hour post-prandial glucose levels (mg/dl)</td>
<td>-143.28 ± 10.73</td>
<td>-2.52 ± 10.49</td>
<td>-140.94 (-159.96 to -121.842)</td>
</tr>
<tr>
<td>Glucose excursion (mg/dl)</td>
<td>-127.62 ± 10.37</td>
<td>2.52 ± 9.76</td>
<td>-129.96 (-148.41 to -111.672)</td>
</tr>
<tr>
<td>Average 7-point self-monitoring of plasma glucose (mg/dl)</td>
<td>34.38 ± 4.90</td>
<td>10.08 ± 4.88</td>
<td>-24.3 (-33.174 to -15.498)</td>
</tr>
</tbody>
</table>

CI = confidence interval; LS = least squares.

HbA1C <6.5 % and <7% were 17.8 % and 35.6 %, respectively, compared with 1.3 % and 5.2 %, respectively, in the placebo group (p<0.0001). Other measures of efficacy also were significantly improved (see Table 3).28

---

**References**

1. Exenatide groups.29
2. Placebo from the GetGoal-L-Asia Study 28
Diabetes Management

Adverse Effects

Gastrointestinal Adverse Reactions

Gastrointestinal adverse reactions to lixisenatide were frequently observed in clinical trials. Nausea was the most frequent event – the incidence ranged from 20 % to 40 % in the lixisenatide arm compared with 4–5 % in the placebo arm. It was transient and dose-dependent. Other reported gastrointestinal reactions included vomiting, diarrhoea, constipation, dyspepsia, abdominal distension and abdominal pain. In the GetGoal-X study, nausea was experienced less frequently with lixisenatide 20 μg once daily (24.3 %) than with exenatide 10 μg twice daily (35.1 %) [p<0.05]. Incidences of diarrhoea (10.4 % and 13.3 %) and vomiting (10.1 % and 13.3 %) in the lixisenatide and exenatide groups, respectively, were also similar.

Hypoglycaemia

Symptomatic hypoglycaemia has been reported with lixisenatide as monotherapy and in combination with other diabetes agents and/or insulin. No cases of severe hypoglycaemia has been reported. Symptomatic hypoglycaemia was reported in more patients on lixisenatide 20 μg once daily added to basal insulin and/or sulfonylurea (42.9 %) than in patients on placebo (23.6 %).

The rate of symptomatic hypoglycaemia in the lixisenatide group was reduced if patients taking a sulfonylurea were excluded (lixisenatide 31.8 %, placebo 28.3 %). The risk of symptomatic hypoglycaemia was not significantly increased with lixisenatide 20 μg once daily as an add-on to sulfonylurea with or without metformin compared to placebo at week 24.

In the GetGoal-X study, patients taking lixisenatide had six-fold fewer hypoglycaemic events and three-fold fewer instances of symptomatic hypoglycaemia (2.5 %) than patients taking exenatide (7.9 %) [p<0.05].

Antibodies to Lixisenatide

It is postulated that antibody formation may decrease the effect of GLP-1 agonists on glucose control. The rate of antibody formation in patients treated with lixisenatide ranged from 43.1 % with lixisenatide 10 μg once daily to 71.2 % with lixisenatide 20 μg twice daily; however, no differences were observed in the efficacy and safety profile of lixisenatide when given to patients with or without antibodies.

Other Reported Adverse Effects

Reported rates of dizziness and headache with lixisenatide are similar to those reported in placebo groups. One patient taking lixisenatide 30 μg once daily experienced loss of consciousness of a few seconds’ duration, which led to withdrawal from the study. One patient taking lixisenatide 10 μg once daily discontinued the medication three weeks into the study following two separate allergic reactions 10 minutes after receiving the drug; on the first occasion, the patient developed pruritis, and three days later the patient had swollen lips and tongue and difficulty breathing. The events were resolved with an oral antihistamine. Two cases of urticaria occurred with lixisenatide (compared to three with placebo).

Potential Role of Lixisenatide Among Glucagon-like Peptide-1 Receptor Agonist Medications

Exenatide, the first incretin-based therapy, was launched in 2005. The novel mechanisms of action of GLP-1 agonists and their multiple associated benefits make them desirable options for the treatment of type 2 diabetes. The second incretin-based therapy to be approved, liraglutide, overcame some of the disadvantages of exenatide, including the need for multiple daily injections timed with meals and a relatively high incidence of nausea. Once-weekly exenatide (Bydureon®), Amylin Pharmaceuticals, Inc., Lilly USA, LLC, and Alkerma, Inc.) has been approved for use in Europe and is currently under review by the US Food and Drug Administration. Once-weekly administration will appeal to many patients, although the delivery system may not be as simple or as comfortable as those of the shorter-acting medications in this class. Medical providers will be able to offer patients the choice between the convenience of the once-weekly injection and the simplicity of the once-daily devices.

Review of the available data suggests that lixisenatide will be effective as a once-daily GLP-1 receptor agonist. Although it has a short half-life, similar to that of exenatide, its biological effects appear prolonged, perhaps due its higher affinity to the GLP-1 receptor. Once-daily administration of lixisenatide and twice-daily administration of exenatide achieved similar lowering of HbA1C levels in the GetGoal-X study.

Lixisenatide has not been compared with liraglutide, the other once-daily GLP-1 agonist. Because liraglutide has a substantially longer half-life, it may reduce fasting plasma glucose more effectively than lixisenatide; however, potential slowing of gastric emptying with lixisenatide may result in greater improvements in post-prandial glucose levels. Additional clinical trials are required to confirm this. Data from further clinical trials and post-approval clinical experience will help clinicians decide how well lixisenatide compares with other GLP-1 agonists.

Sanofi press release, Sanofi Getgoal programme on Lyxumia.


23. Huber J, Janecek E, Meister S, et al., Cardiogenic effect of GLP-1 receptor agonist lixisenatide on ischemia-reperfusion-induced injury in the isolated rat heart, Diabetes, 2011;60(Suppl. 1).


26. Sandof press release, Sanofi Gedeon programme on Lixyma (lixisenatide), an add-on to basal insulin, shows significant positive glucose results, June 3, 2011.


28. Seino Y, Min K, Niemelö E, Takahara A, Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin +/- SU, Diabetes, 2011;60(Suppl. 1).

29. Rosenqvist L, Racic D, Koranyi J, et al., Efficacy and safety of lixisenatide once-daily vs exenatide twice-daily in type 2 DM inadequately controlled on metformin, Diabetes, 2011;60(Suppl. 1).


39. ClinicalTrials.gov, identifier NCT01169779, Efficacy and safety of lixisenatide once-daily in combination with basal insulin in subjects with type 2 diabetes inadequately controlled on metformin, Diabetes, 2011;60(Suppl. 1).


